,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-04']
#asco2022 destiny-04, modi, cont. pfs stat sig with 10.1 vs 5.4 mo with hr 0.51 for hr positive and similar for all pts. os hr 0.64, 17.5 to 23.9 mo. for hr pos with similar all patients results. forrest plot shows no differences. safety profile similar to prior t-dxd trials.
Professor of Medicine, Stanford University; breast cancer doc